<?xml version="1.0" encoding="UTF-8"?>
<p>Current applications: tocilizumab is a recombinant humanized monoclonal antibody directed against the IL-6 receptor (IL-6R). It has been approved by the FDA for the treatment of severe chimeric antigen receptor (CAR) T cell-induced CRS, giant cell arteritis, rheumatoid arthritis (RA), and polyarticular or systemic juvenile arthritis [
 <xref rid="REF35" ref-type="bibr">35</xref>,
 <xref rid="REF36" ref-type="bibr">36</xref>]. 
</p>
